Cargando…

GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy

Pre-operative (neoadjuvant) or post-operative (adjuvant) taxane-based chemotherapy is still commonly used to treat patients with triple-negative breast cancer (TNBC). However, there are still no effective biomarkers used to predict the responsiveness and efficacy of taxane-based chemotherapy in TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Shun-Wen, Chen, Po-Chih, Ger, Tzong-Rong, Chiu, Hui-Wen, Lin, Yuan-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001168/ https://www.ncbi.nlm.nih.gov/pubmed/33809079 http://dx.doi.org/10.3390/jpm11030197

Ejemplares similares

GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer
por: Cheng, Shun-Wen, et al.
Publicado: (2021)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer
por: Chou, Ching-Wen, et al.
Publicado: (2021)

High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy
por: Lin, Yuan‐Feng, et al.
Publicado: (2018)

The role of taxanes in triple-negative breast cancer: literature review [Corrigendum]
Publicado: (2015)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2018)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Molassiotis, Alex, et al.
Publicado: (2019)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Murine Gbp1 and Gbp2 are ubiquitinated independent of Toxoplasma gondii infection
por: Encheva, Vesela, et al.
Publicado: (2018)

A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy
por: Cheng, Pu, et al.
Publicado: (2017)

Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC
por: Brodie, Seth A., et al.
Publicado: (2014)

Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials
por: Huang, Qionglian, et al.
Publicado: (2022)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis
por: Guo, Sanxing, et al.
Publicado: (2020)

The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
por: Zhou, Wenbin, et al.
Publicado: (2012)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice
por: O’Shaughnessy, Joyce, et al.
Publicado: (2021)

Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors
por: Baram, Tamir, et al.
Publicado: (2021)

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2020)

A pharmacophore‐based classification better predicts the outcomes of HER2‐negative breast cancer patients receiving the anthracycline‐ and/or taxane‐based neoadjuvant chemotherapy
por: Li, Xuan, et al.
Publicado: (2021)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India
por: Lakshmaiah, K.C., et al.
Publicado: (2017)

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
por: Li, Meiying, et al.
Publicado: (2018)

Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer
por: Liao, Gaoming, et al.
Publicado: (2021)

Characteristics of taste alterations in people receiving taxane-based chemotherapy and their association with appetite, weight, and quality of life
por: Kaizu, Mikiko, et al.
Publicado: (2021)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
por: Giordano, Antonio, et al.
Publicado: (2019)

Reliability and Validity of the Turkish Version of Chemotherapy-induced Peripheral Neuropathy Assessment Tool for Breast Cancer Patients Receiving Taxane Chemotherapy
por: Simsek, Neriman Yükseltürk, et al.
Publicado: (2018)

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
por: Gómez-Miragaya, Jorge, et al.
Publicado: (2017)

Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients
por: Lusho, Sejdi, et al.
Publicado: (2021)

TTK is a favorable prognostic biomarker for triple-negative breast cancer survival
por: Xu, Qianqian, et al.
Publicado: (2016)

Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
por: van Haren, Frank, et al.
Publicado: (2021)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Clinical characteristics of colitis induced by taxane-based chemotherapy
por: Chen, Ellie, et al.
Publicado: (2020)

Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy
por: González, Myriam, et al.
Publicado: (2021)

LPS-aggregating proteins GBP1 and GBP2 are each sufficient to enhance caspase-4 activation both in cellulo and in vitro
por: Dickinson, Mary S., et al.
Publicado: (2023)

GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma
por: Liu, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fen02ebrl3t0ok7isbm0uhah7p